Results 61 to 70 of about 315,361 (205)

Evidence that the T cell antigen receptor may not be involved in cytotoxicity mediated by gamma/delta and alpha/beta thymic cell lines. [PDF]

open access: yes, 1987
After culture in IL-2, thymocytes expressing either TCR-alpha/beta or -gamma/delta acquired the ability to lyse hematopoietic and solid tumor cell targets without deliberate immunization or apparent restriction by the MHC.
Gemlo, BT   +4 more
core   +1 more source

Visfatin reduces gap junction mediated cell-to-cell communication in proximal tubule-derived epithelial cells [PDF]

open access: yes, 2013
Background/Aims: In the current study we examined if the adipocytokine, visfatin, alters connexin-mediated intercellular communication in proximal tubule-derived epithelial cells.
Hills, Claire E.   +3 more
core   +2 more sources

Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2Cnull Human Immunodeficiency Virus-Infected Individuals

open access: yesViruses, 2019
Expansion of natural killer (NK) cells expressing NKG2C occurs following human cytomegalovirus (HCMV) infection and is amplified by human immunodeficiency virus (HIV) co-infection.
Emilie M. Comeau   +3 more
doaj   +1 more source

Generation of CD16A gene knockout human embryonic stem cell line using CRISPR/Cas9

open access: yesStem Cell Research, 2022
CD16A is a receptor for the Fc portion of immunoglobulin G, and is involved in the antibody dependent cellular cytotoxicity (ADCC) of nature killer cells(Zhu et al., 2020) and antibody dependent enhancement (ADE) of virus infections(Wan et al., 2020 ...
Shunjie Wu   +4 more
doaj   +1 more source

Analysis of radiation-induced cell death in head and neck squamous cell carcinoma and rat liver maintained in microfluidic devices [PDF]

open access: yes, 2013
Objective The aim of this study was to investigate how head and neck squamous cell carcinoma (HNSCC) tissue biopsies maintained in a pseudo in vivo environment within a bespoke microfluidic device respond to radiation treatment.
Burcombe R   +27 more
core   +2 more sources

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

open access: yesNature Communications
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish ...
C. Grandclément   +29 more
doaj   +1 more source

The activating receptors 2B4 and NTB-A, but not CRACC are subject to ligand-induced down-regulation on human natural killer cells [PDF]

open access: yes, 2010
Activation of natural killer cells can be mediated by different receptors. Stimulation of the receptors 2B4, NTB-A and CRACC, members of the SLAM-related receptor family, induces cytotoxicity and cytokine production.
Carolin Böhm   +4 more
core   +2 more sources

In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells [PDF]

open access: yes, 2019
Much effort has been made to try to understand the relationship between chemotherapeutic treatment of cancer and the immune system. Whereas much of that focus has been on the direct effect of chemotherapy drugs on immune cells and the release of antigens
A Ashkenazi   +32 more
core   +2 more sources

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

open access: yesPLoS Biology, 2016
IgG antibodies can organize into ordered hexamers on cell surfaces after binding their antigen. These hexamers bind the first component of complement C1 inducing complement-dependent target cell killing.
Rob N de Jong   +12 more
doaj   +1 more source

Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice

open access: yesBlood Advances, 2017
: Immunotherapy has proven beneficial in many hematologic and nonhematologic malignancies, but immunotherapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is hampered by the lack of tumor-specific targets.
Marijn A. Gillissen   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy